Neutra Life Sciences Expands Clinical Research Portfolio Through Strategic Joint Ventures

Neutra Life Sciences, a subsidiary of Neutra Corp, has taken a significant step forward in the clinical research industry by establishing joint venture partnerships with several specialized medical practices. These partnerships include collaborations with Epic Foot & Ankle Centers, Aspire Hospital Cancer Centers, and Radiant Dermatology & Aesthetics Clinic, enabling the company to diversify its clinical research offerings into podiatry, radiation oncology, and dermatology.

This strategic expansion allows Neutra Life Sciences to address a broader patient population and meet the increasing demand for specialized clinical research. By diversifying its portfolio, the company not only strengthens its leadership in the clinical research space but also enhances its capacity to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. Sydney Jim, President and CEO of Neutra Corp, highlighted the significance of this growth, noting its alignment with the demand for high-quality, integrated clinical research solutions and its potential to foster innovation in patient care and research.

In a move to further concentrate on its life sciences and clinical research endeavors, Neutra Corp has also announced the divestiture of its hemp-based cannabis subsidiary, VIVIS Corporation. This decision reflects the company's commitment to advancing healthcare through research and development, focusing on sectors with greater regulatory stability and long-term growth prospects.

Neutra Life Sciences' expansion into additional medical specialties is a testament to its mission of improving health outcomes through innovative collaboration and research. By building a comprehensive network of clinical research sites and delivering superior services to its partners, the company underscores its dedication to the advancement of clinical research and patient care.